Precision Molecular, Inc. (PMI) is at the forefront of cancer care, specializing in the development of innovative radiopharmaceuticals and molecular imaging agents. The company focuses on targeted alpha-particle therapy, particularly utilizing Astatine-211 labeled agents to precisely target cancer cells. PMI's approach to molecular imaging distinguishes itself from traditional anatomic imaging techniques, such as MRI and CT, by measuring biological processes with enhanced specificity. This capability allows for earlier detection of diseases, potentially leading to more effective treatments. PMI's pipeline includes several promising candidates, such as PMI05 and PMI06, which are designed to target specific cancer markers like carbonic anhydrase IX (CAIX) and programmed death-ligand 1 (PD-L1), respectively.

The company's scientific platform emphasizes the concept of "Precision as a Service," leveraging advanced molecular imaging technologies to visualize and quantify biological processes at the cellular level. PMI's radiopharmaceuticals are designed to be both diagnostic and therapeutic, embodying the theranostic approach that allows for the simultaneous imaging and treatment of cancer. This dual functionality is exemplified in their development of agents that can switch from imaging isotopes to therapeutic isotopes, enhancing the potential for personalized cancer care. With a strong focus on high-value theranostic targets, PMI aims to revolutionize cancer detection and treatment by addressing both tumors and their surrounding microenvironments.

United States

Precision Molecular (PMI) is a clinical-stage company developing imaging biomarkers and theranostics for patients with cancer. They specialize in molecular imaging.

Precision Molecular

Company Details